India's healthcare marketing landscape is multi-tier: metro CPCs differ from tier-2 by 2-3×; specialty CPLs differ by 4-6×; AEO visibility differs by language and search behaviour. ICG runs India-wide engagements with city-level calibration baked in.
The Indian IVF market — the numbers that matter for marketing
The Indian IVF market context is essential for any national marketing programme — because the market is large, growing rapidly, and poorly served by most marketing infrastructure currently in place. The estimated number of infertile couples in India is 27.5 million (ICMR data). The estimated number of IVF clinics in India is approximately 3,000 (NATHEALTH). The IVF market is growing at approximately 12% CAGR (IBEF Healthcare Report). The market value is approximately ₹4,200 crore (FY25, estimated) and projected to cross ₹8,000 crore by 2030.
What these numbers mean for marketing: there is enough demand for many national-scale IVF brands to coexist; brand consolidation has not happened to anything like the extent it could; the marketing CAC dynamics still reward the operator that gets the architecture right (most haven't); and the international acquisition opportunity is materially under-monetised by Indian IVF brands.
The 4 IVF patient archetypes — and why national marketing must reach all four
A national IVF marketing programme that treats IVF patients as a single audience will under-perform on every archetype. The four archetypes each have distinct demographics, decision processes, attribution chains, and conversion economics.
Archetype 1 — Urban professional couples (30s-40s, primary infertility). Highest-volume archetype. Female partner initiates online research (in 67% of cases per ICG data); male partner enters decision in weeks 4-8. 12-18 month decision cycle from first awareness to first cycle. CPQL high (₹1,400-2,200 ICG range across cities) but conversion-to-treatment rate also high (28-38%). Marketing focus: SEO content depth, YouTube authority, doctor brand signals, paid retargeting calibrated to the 90-180 day cycle.
Archetype 2 — Secondary infertility couples (35+, second child). Different psychology, different information needs. Decision cycle is faster (60-120 days) because the patient has prior fertility experience. CPQL moderate. Marketing focus: emotional positioning, NMC-compliant testimonial content, doctor-relationship-led acquisition.
Archetype 3 — International medical tourism patients. 70-80% pricing advantage of Indian IVF over UK/US/Australia/Gulf-origin treatment. Longer attribution timeline (180-365 days from first enquiry to treatment). WhatsApp-dominant channel for Gulf inbound; email-dominant for UK/US. Multi-language content (English, Arabic). Lower per-patient CAC at volume.
Archetype 4 — Male-factor patients (rarely self-identified). Brought into the process by partner. Distinct content programme (azoospermia, sperm motility, varicocele, ICSI). Under-served by most Indian IVF marketing. ICG's national programmes include male-factor content as a parallel track from day one.
Regional CPQL variation — the national operating model
A single national IVF marketing budget split equally across major metros will materially under-perform a budget that is allocated by regional CPQL variation. The Q2 2026 ICG benchmark shows: Mumbai IVF CPQL +20% above national median, Delhi +15%, Bangalore +10%, Hyderabad −5%, Chennai −10%. The implication for a national IVF chain: a Mumbai-resident IVF clinic should run with a higher CPQL target than a Hyderabad-resident clinic — and the national reporting framework should normalise for this regional variation rather than treating all locations as comparable.
The seasonal variation is also material at national scale. Q4 (October-December) is the highest demand period across India — couples plan for year-end cycle initiation. Q1 is the second-highest. Q2-Q3 (April-August) is the softest period, with CPQL rising 15-25% above Q4 levels. National IVF chains concentrate 35-45% of annual budget in Q4 to capture the demand peak.
The ART (Regulation) Act 2021 — the national IVF marketing regulatory layer
The ART (Regulation) Act 2021 and the Surrogacy (Regulation) Act 2021 establish the national regulatory framework that every IVF marketing programme operates within. The ART Act requires all ART clinics to be registered with the National ART and Surrogacy Registry and prohibits certain forms of promotional communication. The Surrogacy Act prohibits commercial surrogacy promotion entirely. The NMC Code of Professional Ethics (2026 revision) Section 6 prohibits outcome guarantees, before-and-after imagery of identifiable patients, and paid testimonials in clinical advertising.
ICG builds national IVF marketing programmes within all three regulatory frameworks. Every creative asset, landing page, and content piece passes a pre-publication regulatory check before going live. Compliance-first design avoids the cost of an enforcement complaint — which is materially higher than the cost of building compliant content from the start.
